The Study
Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and its kidney clearance: post-hoc analyses of four clinical trials
This study looked at how a type of diabetes medicine affects a substance called uric acid in the urine, but it didn’t test this on purpose — it just looked back at old data from four smaller studies. So we can say the medicine sometimes changed uric acid levels, but we can’t say it caused those changes or that it helps your kidneys because of it.
Analysis score
Maximum 100 for a systematic review with meta-analysis.
Where the score came from
This study looked at whether drugs like exenatide, liraglutide, and lixisenatide — used for weight loss and diabetes — change how much uric acid the kidneys remove.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 557 / 100
Quality score
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Even though uric acid excretion spiked right after a shot, it didn't last — and didn't lower blood levels.
- 2So it's unlikely this effect helps protect the heart or kidneys.
- 3A single IV dose of exenatide made kidneys dump 1.58 mg/min/1.73m² more uric acid in healthy people and 0.75 mg/min/1.73m² in diabetics.
- 4But after weeks of daily pills, uric acid levels didn't change at all.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Diabetes, obesity & metabolism
Year
2018
Authors
L. Tonneijck, M. Muskiet, M. Smits, P. Bjornstad, M. Kramer, M. Diamant, E. Hoorn, J. Joles, D. V. van Raalte
Related Content
Claims (6)
Weight loss caused by GLP-1 receptor agonists is associated with lower levels of uric acid in the blood.
Intravenous exenatide increases the amount of uric acid removed in urine by a specific amount in overweight men and in overweight adults with type 2 diabetes, but does not reliably reduce uric acid levels in the blood.
In people with type 2 diabetes, long-term use of GLP-1 receptor agonists does not consistently change uric acid levels in the blood or urine, and the heart and kidney benefits of these drugs occur through other mechanisms.
In overweight adults with type 2 diabetes and normal uric acid levels, treatment with liraglutide for 12 weeks or lixisenatide for 8 weeks does not change the amount of uric acid in the blood or excreted in urine, even when weight decreases and blood sugar improves.
A single dose of exenatide increases the pH and sodium content of urine in overweight adults, regardless of diabetes status, and this is accompanied by a proportional increase in uric acid excretion, indicating a common kidney tubule process involving the Na⁺/H⁺ exchanger type 3.
In overweight adults with type 2 diabetes, a single dose of exenatide causes uric acid to be excreted in the same way regardless of how much uric acid was already in the blood before the dose.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.